Vyxeos liposomal 44 mg/100 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionsdispersion - 2 Swissmedic Key 68014002 Registration Holder MEDA Pharmaceuticals Switzerland GmbH Name Vyxeos liposomal 44 mg/100 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionsdispersion Date of registration 17.02.2022 Introduction of Sequence 17.02.2022 ATC-Classification Cytarabine and Daunorubicin (L01XY01) Revision date WHO WHO-DDD Valid until 16.02.2027 Index Therapeuticus (BSV) Show package size 2 Index Therapeuticus (Swissmedic) 07.16.10. Description Swissmedic categorie. A SL Eintrag No Indication Information for professionals IP Consumer information Ex-factory-Price PR Deductible k.A. Consumer price PR Feedback FB GTIN 7680680140024 Medication Code Synthetika Pharmacode Disponibility
Composition cytarabinum 100 mg, daunorubicinum 44 mg, distearoylphosphatidylcholinum, distearoylphosphatidylglycerolum natricum, cholesterolum, cupri(II) d-gluconas, trolaminum, saccharum, pro vitro. Packungsbestandteile Galenic Form Excipiens Active Agent Dose Cytarabine 100 mg Daunorubicin 44 mg
Inactive agents Cholesterol Cupri(ii) D-gluconas Saccharum
Source Data was imported : 08.11.2023
Swissmedic Registration :
Sequence :
Product name :
Registration owner: :
Product group :
Index Therapeuticus (BSV) :
Medication Code :
Date of registration :
Valid until :
Package number :
Show package size :
Commercial Form/Unit :
Swissmedic categorie. :
Active Agents :
Composition :
